Palvella (PVLA) news
Recent news
Palvella's Qtorin phase 3 met primary endpoint
AInvest Wire · 9h agoPalvella's completes Qtorin NDA submission to FDA
Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced on June 29, 2026, that it has submitted the first module of its rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for QTORIN™ 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations…
AInvest Wire · 9h agoPalvella Therapeutics - Accelerating U.S. launch readiness for potential Qtorin rapamycin launch in H1 2027 if approved
Palvella Therapeutics (Nasdaq: PVLA) is advancing its preparations for a potential U.S. commercial launch of QTORIN™ rapamycin in the first half of 2027, should the therapy receive FDA approval. The company has submitted the first module of its rolling New Drug Application (NDA) for the treatment…
AInvest Wire · 9h agoPalvella Therapeutics - expects to complete NDA submission in H2 2026
AInvest Wire · Jun 29, 2026Palvella Therapeutics: still on track to submit Qtorin NDA in 2H
Palvella Therapeutics (Nasdaq: PVLA) remains on track to submit a New Drug Application (NDA) for QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations in the second half of 2026, as previously outlined in its corporate update in May 2026 . The company reported positive topline…
AInvest Wire · Jun 3, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.